We Use NK Cells to Kill Cancer

At Dragonfly we invent therapies that harness the body's
immune system, for vastly improved patient outcomes.

THE LATEST AT DRAGONFLY THERAPEUTICS

THE CHALLENGE

Cancer is the Leading Cause of Death Worldwide

Cell..jpg

INSPIRATION

Breakthrough Discoveries, Renegade Scientists, and Patients Fighting Cancer
That We Find Inspiring

OUR TECHNOLOGY

3d-illustration-of-a-cancer-cell-and-lym

Dragonfly's Proprietary TriNKETs Activate the Body's NK Cells and Mobilize T Cells + Other Cells of the Adaptive Immune System

Our Partners in the Fight to End Cancer

DKFZ_Logo-3zu-Research_en_Black-Blue_sRG

1280px-Merck_Logo.svg.png

DRAGONFLY IN THE NEWS

Dragonfly launches a Phase I study for their lead drug DF1001 in HER2 expressing solid tumors. This is the first of their TriNKET platform drugs to go into humans. We have also partnered with Abbvie to work on cancer drugs as well as autoimmune diseases.